[wpml_language_selector_widget]
[wpml_language_selector_widget]

Resources

Treatment Guidelines

Guidelines Link to guidelines
NCCN (V2.2025) https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf

FDA approved drugs for NHL

GlofitamabColumvi®https://www.drugs.com/pro/fludarabine.html

Generic nameTrade nameAddress
AcalabrutinibCalquence®https://www.calquence.com/
Axicabtagene ciloleucelYescarta®https://www.yescarta.com/
BendamustineBendeka®https://www.bendeka.com/
Brentuximab vedotinAdcetris®https://www.adcetris.com/
Brexucabtagene autoleucelTecartus®https://www.tecartus.com/
CyclophosphamideGenerichttps://www.drugs.com/pro/cyclophosphamide.html
DoxorubicinGenerichttps://www.drugs.com/mtm/doxorubicin.html
Epcoritamab-bysbEpkinly®https://www.epkinly.com/
FludarabineGenerichttps://www.drugs.com/pro/fludarabine.html
GlofitamabColumvi®https://www.columvi.com/
Ibritumomab tiuxetanZevalin®https://zevalin.com/wp-content/uploads/2019/04/PI-ZEVALIN-092019.pdf
IbrutinibImbruvica®https://www.imbruvica.com/
LenalidomideRevlimid®https://www.revlimid.com/
Lisocabtagene maraleucelBreyanzi®https://www.breyanzi.com/
Loncastuximab tesirine-lpylZynlonta®https://www.zynlonta.com/
Mosunetuzumab-axgbLunsumio®https://www.lunsumio.com/
OfatumumabArzerra®https://www.us.arzerra.com/
ObinutuzumabGazyva®https://www.gazyva.com/
PembrolizumabKeytruda®https://www.keytruda.com/
Polatuzumab vedotin-piiqPolivy®https://www.polivy.com/
PrednisoneGenerichttps://www.drugs.com/prednisone.html
RituximabRituxan®https://www.rituxan.com/
SelinexorXpovio®https://www.xpovio.com/
Tafasitamab-cxixMonjuvi®https://www.monjuvi.com/
TazemetostatTazverik®https://www.tazverik.com/
TisagenlecleucelKymriah®https://www.kymriah.com/
VenetoclaxVenclexta®https://www.venclexta.com/
VincristineVincasar®https://www.drugs.com/pro/vincasar-pfs.html
ZanubrutinibBrukinsa®https://www.brukinsa.com/

Ongoing clinical trials and new therapeutics for DLBCL1

Agent Agent type Combined agent Study
Odronextamab CD20xCD3 bispecific antibody – NCT03888105
Ibrutinib BTK inhibitor ABT-199, prednisone, obinutuzumab, lenalidomide NCT03223610
Nemtabrutinib BTK inhibitor – NCT03162536
LOXO-305 BTK inhibitor Venetoclax, R-CHOP NCT03740529
Acalabrutinib BTK inhibitor pembrolizumab NCT02362035
Valemetostat EZH1/2 dual inhibitor – NCT02732275
Vorinostat HDACi R-CHOP NCT00972478
Chidamide HDACi – NCT03201471
Odronextamab Bispecific antibody – NCT02290951
Odronextamab Bispecific antibody – NCT03888105

Resources

ResourceAddress
American Cancer Society (ACS). What Is Non-Hodgkin’s Lymphoma?https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html
American Cancer Society (ACS) Non-Hodgkin.https://www.cancer.org/cancer/types/non-hodgkin-lymphoma.html
CancerCarehttps://www.cancercare.org/professionals
Leukemia & Lymphoma Society. Non-Hodgkin Lymphoma.https://www.lls.org/lymphoma/non-hodgkin-lymphoma
Lymphoma Research Foundation. Non-Hodgkin Lymphoma.https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/
Mayo Clinic. Non-Hodgkin’s lymphoma.https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/symptoms-causes/syc-20375680
MedlinePlus. Non-Hodgkin lymphoma.https://medlineplus.gov/ency/article/000581.htm
National Cancer Institute. Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version.https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
US National Library of Medicine. Clinical Trials.https://clinicaltrials.gov/

ALL URLs accessed October 27, 2025

References

  1. Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13:175. doi:10.1186/s13045-020-01011-z
  2. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol. 2021;39:1959-1970. doi:10.1200/JCO.20.03175
  3. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055-1065. doi:10.1016/S1470-2045(22)00335-7
  4. Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20xCD3 bispecific antibody in patient with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicenter, phase 1 trial. Lancet Haem. 2022;9:e327-e339. doi:10.1016/S2352-3026(22)00072-2
  5. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study. 2021;398:1157-1169. doi:10.1016/S0140-6736(21)00889-8
  6. Cahill KE, Smith SM. Follicular lymphoma: A focus on current and emerging therapies. Oncology (Williston Park). 2022;36:97-106. doi:10.46883/2022.25920946

Defining NHL

Pathogenesis

Diagnosis & Staging

Treating & Managing NHL

Guidelines

Understanding AEs

Patient Support Strategies

Resources

Pin It on Pinterest

Directory
Scroll to Top

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers